title: Moxifloxacin susceptibility mediates the relationship between causative organism and clinical outcome in bacterial keratitis.
abstract: OBJECTIVE
  Bacterial keratitis is a sight-threatening infection of the cornea that is one of the leading causes of blindness globally. In this report, we analyze the role of moxifloxacin susceptibility in the relationship between causative organisms and clinical outcome in bacteria keratitis.
  
  
  METHODS
  A mediation analysis is used to assess the role of moxifloxacin susceptibility in the relationship between causative organisms and clinical outcome in bacterial keratitis using data collected in a randomized, controlled trial.
  
  
  RESULTS
  In the Steroids for Corneal Ulcers Trial (SCUT), 500 corneal infections were treated with topical moxifloxacin. The outcome of 3-week best spectacle-corrected visual acuity was significantly associated with an organism (Streptococcus pneumoniae, Pseudomonas aeruginosa, etc., P = 0.008). An indirect effects mediation model suggests that MIC accounted for approximately 13% (95% confidence interval, 3%-24%, P = 0.015) of the effect of the organism on 3-week visual acuity.
  
  
  CONCLUSIONS
  Moxifloxacin mediates the relationship between causative organisms and clinical outcome in bacterial keratitis, and is likely on the causal pathway between the organism and outcome. (ClinicalTrials.gov number, NCT00324168.).
authors: Francis I. Proctor Foundation, University of California–San Francisco, 513 Parnassus Avenue, Room S309, San Francisco, CA 94117, USA.
authors: Catherine E
authors: CE
authors: Oldenburg
authors: Prajna
authors: P
authors: Lalitha
authors: Muthiah
authors: M
authors: Srinivasan
authors: Palanisamy
authors: P
authors: Manikandan
authors: M Jayahar
authors: MJ
authors: Bharathi
authors: Revathi
authors: R
authors: Rajaraman
authors: Meenakshi
authors: M
authors: Ravindran
authors: Jeena
authors: J
authors: Mascarenhas
authors: Natalie
authors: N
authors: Nardone
authors: Kathryn J
authors: KJ
authors: Ray
authors: David V
authors: DV
authors: Glidden
authors: Nisha R
authors: NR
authors: Acharya
authors: Thomas M
authors: TM
authors: Lietman
mesh_terms: D000287:Administration, Topical; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001372:Aza Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D001419:Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D003320:Corneal Ulcer / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*; D004198:Disease Susceptibility; D004311:Double-Blind Method; D015818:Eye Infections, Bacterial / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*; D024841:Fluoroquinolones; D006801:Humans; D008826:Microbial Sensitivity Tests; D000077266:Moxifloxacin; D009883:Ophthalmic Solutions / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D011804:Quinolines / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome; D014792:Visual Acuity / Q000502:physiology
chemical_list: D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D009883:Ophthalmic Solutions; D011804:Quinolines; D011239:Prednisolone; D000077266:Moxifloxacin
references: Clin Infect Dis. 2012 May;54(10):1381-7
references: 22447793
references: Invest Ophthalmol Vis Sci. 2010 Jan;51(1):362-8
references: 19684005
references: Clin Exp Optom. 2002 Sep;85(5):271-8
references: 12366347
references: Behav Res Methods Instrum Comput. 2004 Nov;36(4):717-31
references: 15641418
references: Arch Ophthalmol. 2012 Feb;130(2):143-50
references: 21987582
references: Bull World Health Organ. 2004 Nov;82(11):844-51
references: 15640920
references: Am J Ophthalmol. 2008 Mar;145(3):409-412
references: 18207124
references: Cornea. 2008 Jan;27(1):22-7
references: 18245962
references: J Fr Ophtalmol. 2011 Jun;34(6):362-8
references: 21507512
references: Indian J Med Microbiol. 2002 Jan-Mar;20(1):19-24
references: 17657018
references: Br J Ophthalmol. 2010 Mar;94(3):384-5
references: 20215380
references: Graefes Arch Clin Exp Ophthalmol. 2012 Mar;250(3):369-74
references: 22116498
references: Ophthalmic Epidemiol. 2007 Mar-Apr;14(2):61-9
references: 17464852
references: Br J Ophthalmol. 2002 Nov;86(11):1211-5
references: 12386069
references: Arch Ophthalmol. 2012 Feb;130(2):151-7
references: 21987581
references: J Cataract Refract Surg. 2011 Oct;37(10):1822-31
references: 21865006
references: Ophthalmology. 2012 Sep;119(9):1785-90
references: 22627118
references: Cornea. 2012 Jun;31(6):662-7
references: 22333662
references: Arch Ophthalmol. 2003 Sep;121(9):1229-33
references: 12963604
references: Br J Ophthalmol. 2011 Jun;95(6):762-7
references: 21478201
references: Eye Contact Lens. 2010 Jul;36(4):195-200
references: 20626115
references: Clin Infect Dis. 2002 Oct 15;35(8):982-9
references: 12355386
references: Nepal J Ophthalmol. 2012 Jan-Jun;4(1):119-27
references: 22344009